Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

(TM), a late-stage vaccine candidate for the treatment of advanced prostate cancer, was acquired as part of the partnership that was entered with the National Cancer Institute. Very promising data were reported, showing prolonged survival combined with a favourable safety profile. Phase III studies expected to be initiated in 2010. - MVA-BN(R) Anthrax, a new preclinical programme for an anthrax vaccine, is expected to enter clinical trials in 2010. - MVA-BN(R) HIV multiantigen, in development as prophylactic and therapeutic vaccine against HIV, initiated clinical Phase I/II trials. - The company's MVA-BN(R) based prostate cancer vaccine also entered clinical Phase I/II trials. - A milestone payment of USD 25 million was received after submission of important IMVAMUNE(R) data. - The data that were generated from a larger Phase II study with IMVAMUNE(R) was submitted to the US health authorities for evaluation whether they can potentially support the use of IMVAMUNE(R) in a declared emergency. - More than 2,400 subjects have now been vaccinated with IMVAMUNE(R) - The first IMVAMUNE(R) contracts outside USA were signed with Canada and an Asian country.

Anders Hedegaard, President & CEO of Bavarian Nordic, said: "2008 was a successful year for Bavarian Nordic where all our primary goals were achieved. We implemented a new strategy, and this has already borne fruit. Our increased focus on cancer therapies which through to the partnership with the NCI led to the acquisition of PROSTVAC(TM) has strengthened our pipeline and we feel very optimistic about our cancer vaccines in the future. At the end of the year, we submitted the important safety data for IMVAMUNE(R) to the US health authorities and are now awaiting just one approval in order to initiate the delivery of the 20 million doses under the RFP-3
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 Reportlinker.com announces ... available in its catalogue: Global ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About ... that are readily decomposed by the action ... non-degradable packaging in terms of raw materials, ...
(Date:8/27/2014)... 27, 2014 Research and Markets ... Lactic Acid  (Biodegradable Polymer, Food & Beverage, Personal ... to 2019" report to their offering. ... with an asymmetrical carbon atom. The main applications ... food and beverage, personal care product, and pharmaceutical ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... The Graphene Opportunity - A Rational View ... Graphene The New Nanotech? A similar amount ... of applications ranging from microelectronics to water treatment, ... announced the availability of the Graphene Opportunity Report, ...
(Date:8/27/2014)... JUNCTION, N.J. , Aug. 27, 2014 ... innovative drug delivery technologies, today announced that it has ... Jersey Business & Industry Association,s 2014 Awards for ... were selected by an independent panel of judges from ... company volunteers. Award winners will be honored at a ...
Breaking Biology Technology:Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2
... SUNNYVALE, Calif., Nov. 13 Voler,( http://www.volersystems.com ) ... design capabilities beyond prototypes and custom test,systems to ... human use.,"Voler continues to invest in upgrades to ... our multidisciplinary team," stated Walt Maclay,president of Voler. ...
... Future Healthcare and Education, OLDSMAR, Fla., Nov. ... largest and most established private,cord blood banks and ... agreement as an exclusive retailer with Upromise(R) the,largest ... Since,2004, Cryo-Cell has been the only cord blood ...
... Requires Only Weekly Dosing, SAN DIEGO, Nov. ... trial data demonstrating that ARX201, the company,s,long-acting human ... Serono, normalized insulin-like growth factor I (IGF-I) levels,while ... adults,with Growth Hormone deficiency. The results of this ...
Cached Biology Technology:Voler Expands Medical Device Design Capabilities 2Voler Expands Medical Device Design Capabilities 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 2Cryo-Cell Renews Upromise Industry-Exclusive Agreement 3Cryo-Cell Renews Upromise Industry-Exclusive Agreement 4Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 2Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated 3
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
(Date:8/26/2014)... have developed algorithms to identify weak spots in tendons, ... technology, which needs to be refined before it is ... strains and tiny injuries in the body,s tissues long ... online Aug. 27 in the Journal of the ... nexus of the physical and life sciences. , "Tendons ...
(Date:8/26/2014)... the University of Warwick have provided the first ... protein is linked to early signs of dementia. ... research found that the absence of the protein ... in the nervous system. These changes were shown ... of dementia, including restricted learning and memory formation ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Lack of naturally occuring protein linked to dementia 2
... FRANCISCOSatellite observations have revealed the first direct evidence of ... sheet, tarnishing the ice with soot and making it ... the American Geophysical Union meeting this week, an Ohio ... and Infrared Pathfinder Satellite Observation (CALIPSO) satellite, which captured ...
... most powerful X-ray laser, has revealed the three dimensional structure ... causes African trypanosomiasis (or sleeping sickness) in humans. ... cathepsin B enzyme, it will be possible to design new ... causes sleeping sickness, leaving the infected human unharmed. The ...
... recent University of Colorado Cancer Center review in the journal ... promising cancer prevention properties. Meanwhile, an ongoing clinical trial is ... of colon cancer. "While I have been trained ... to deliver bioactive, cancer fighting compounds with food, and this ...
Cached Biology News:Fire and ice: Wildfires darkening Greenland snowpack, increasing melting 2X-ray laser helps slay parasite that causes sleeping sickness 2Clinical trial tests rice bran to prevent cancer 2
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
1000X solution used for inducing CopyControl™ based vectors to high copy numbers...
Request Info...
HAS1 (C-14)...
Biology Products: